Pharmacokinetics hormone response and safety profile of multiple ascending doses of elagolix in healthy premenopausal women

Trial Profile

Pharmacokinetics hormone response and safety profile of multiple ascending doses of elagolix in healthy premenopausal women

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 30 Mar 2017 New trial record
    • 16 Feb 2017 Results published in the Journal of Clinical Endocrinology and Metabolism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top